ZVRA
Zevra Therapeutics Inc.
11.40$
+3.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +24.0% | -12.2% | -4.5% | +32.6% | -7.0% | -3.0% | +48.4% | +5.4% | +5.4% | -2.2% | +8.7% | |
| – | -36.5% | -27.7% | -3.2% | +63.3% | -13.5% | -5.2% | +177.5% | -0.5% | -0.9% | +3.1% | +9.3% | |
| – | -0.5% | -0.5% | -8.4% | +37.6% | -37.5% | +10.5% | +27.8% | +14.1% | +14.6% | +53.2% | +52.0% | |
| – | – | – | -6.6% | +81.4% | -22.2% | -9.9% | +223.5% | -1.5% | -4.3% | -50.0% | +131.8% | |
| – | +62.4% | -48.5% | +7.7% | -12.9% | +34.9% | +20.1% | +44.8% | -7.8% | +38.1% | -5.0% | +1.8% | |
| – | – | – | -17.9% | -14.1% | -77.5% | +29.9% | -56.7% | +23.4% | +27.3% | +32.8% | +6.0% | |
| – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | -2.2% | -2.3% | +6.7% | -2.3% | -2.3% | -89.5% | -4.5% | -4.7% | -4.9% | -5.2% | |
| – | +54.5% | -7.2% | +9.2% | +8.8% | +13.7% | -4.9% | +5.6% | -1.5% | -5.0% | -44.1% | +16.9% | |
| – | +239.5% | -59.4% | +1.8% | +13.2% | -1.2% | -20.8% | +6.9% | -9.4% | +50.4% | +19.7% | +3.4% | |
| – | – | – | +2.2% | -9.4% | -22.2% | +40.2% | -10.9% | -16.0% | -5.0% | -3.1% | +54.2% | |
| – | +17.7% | +62.9% | -10.2% | +19.6% | -46.6% | +36.3% | -11.1% | -30.1% | -77.6% | +371.7% | +19.5% | |
| – | -88.5% | +748.8% | +35.7% | +1.0% | +1.0% | +1.0% | +1.0% | +1.0% | +1.0% | – | – | |
| – | -8.3% | -21.1% | -33.5% | +114.8% | -43.1% | +3.4% | +185.8% | +13.6% | +16.1% | +33.1% | +5.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +19.6% | +0.6% | +0.3% | +14.1% | +12.3% | +0.8% | +4.1% | -0.7% | +2.3% | +5.2% | +1.8% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.